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A Specific CNOT1 Mutation Results in a Novel Syndrome
of Pancreatic Agenesis and Holoprosencephaly through
Impaired Pancreatic and Neurological Development
Elisa De Franco,1,11 Rachel A. Watson,2,11 Wolfgang J. Weninger,3 Chi C. Wong,2 Sarah E. Flanagan,1
Richard Caswell,1 Angela Green,2 Catherine Tudor,2 Christopher J. Lelliott,2 Stefan H. Geyer,3
Barbara Maurer-Gesek,3 Lukas F. Reissig,3 Hana Lango Allen,1 Almuth Caliebe,4 Reiner Siebert,4,5
Paul Martin Holterhus,6 Asma Deeb,7 Fabrice Prin,8 Robert Hilbrands,9,10 Harry Heimberg,9 Sian Ellard,1
Andrew T. Hattersley,1,12,* and Ineˆs Barroso2,12,13,*
We report a recurrent CNOT1 de novomissense mutation, GenBank: NM_016284.4; c.1603C>T (p.Arg535Cys), resulting in a syndrome
of pancreatic agenesis and abnormal forebrain development in three individuals and a similar phenotype in mice. CNOT1 is a transcrip-
tional repressor that has been suggested as being critical for maintaining embryonic stem cells in a pluripotent state. These findings
suggest that CNOT1 plays a critical role in pancreatic and neurological development and describe a novel genetic syndrome of pancreatic
agenesis and holoprosencephaly.Discovering genes with mutations causal of pancreatic
agenesis is crucial to identifying factors needed for pancre-
atic development. To date, pathogenic variants in six genes
(PTF1A [MIM: 615935], PDX1 [MIM: 260370], GATA6
[MIM: 600001], GATA4 [MIM: 600576], HNF1B [MIM:
137920], and RFX6 [MIM: 615710]) have been reported
to severely affect pancreatic development and result in
pancreatic agenesis.1 Gene discovery in pancreatic agen-
esis has shown both similarities and marked differences
between pancreatic development in human and mouse.
In both species, complete loss of function of PTF1A,
PDX1, or RFX6 results in pancreatic agenesis. In contrast,
while haploinsufficiency of GATA6 is a common cause of
pancreatic agenesis in humans,2 in mice Gata6 knockout
does not result in abnormal pancreatic development.3
Knowledge of human pancreatic development is essential
to guide progress of beta-cell replacement therapy for peo-
ple with type 1 diabetes.
We investigated an international cohort of 107 individ-
uals diagnosed with pancreatic agenesis—defined by
requiring both endocrine (insulin) and exocrine (pancre-
atic enzymes) replacement therapy within the first
6 months of life—and identified a mutation in a known
gene in 98 of them (Table S1). To identify de novo muta-
tions in the remaining nine subjects, exome sequencing
was performed for the probands and both their unaf-
fected parents when available (n ¼ 7) (Supplemental Sub-
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in CNOT1 (MIM: 604917; GenBank: NM_016284.4;
c.1603C>T [p.Arg535Cys]) in three individuals with
pancreatic agenesis. The variant had arisen de novo in two
of them and was not present in the DNA sample from the
3rd individual’s father (maternal sample was not available
for testing) (Figure 1A, Tables S2 and S3). We confirmed
these results by Sanger sequencing (Supplemental Subjects
andMethods, Figure S1). The p.Arg535Cys variant is absent
fromdbSNP138,DECIPHER, andGnomADandaffects a res-
idue which is highly conserved across species (up to
C. elegans) (Figure 1B). All three in silico prediction tools
used (AlignGVGD, PolyPhen2, and SIFT accessed through
AlamutVisual) predicted the variant to have a deleterious
effect on protein function (Supplemental Subjects and
Methods).
The three individuals who were heterozygous for the
CNOT1 p.Arg535Cys variant had strikingly similar clinical
features (see Supplemental Note). In addition to pancreatic
agenesis, all three had definite (n ¼ 2) or possible holopro-
sencephaly (Figure 1A, Table S4), a disorder in which the
prosencephalon (forebrain of the embryo) fails to develop
into two hemispheres. P01 and P02 (who was previously
reported by Hilbrands et al.4) both had partial/semi-lobar
holoprosencephaly, while P03 has dysmorphic features
which could be consistent with holoprosencephaly (prom-
inent central incisors and occiput, highly arched palate,
and low-set ears) but brainMRI was declined by his parentsool, EX2 5DW Exeter, UK; 2Wellcome Sanger Institute, CB10 1SA Hinxton,
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Figure 1. Genetic and Clinical Findings in Individuals with Pancreatic Agenesis
(A) Partial pedigrees and clinical features of the three individuals with the heterozygous CNOT1 p.Arg535Cys mutation.
(B) Conservation of CNOT1 residues 529 to 568 across 10 representative species. Residue p.Arg535 is highlighted in red. Residues
identical to the human CNOT1 protein are highlighted in blue, differences are highlighted in gray.
(C)CoronalbrainMRIofP02 showingabsenceof theanterior interhemisphericfissure (redarrow), fusionof the frontal lobes (orangearrow),
absenceof frontalhorns (green arrow), absenceof the sylvianfissures (yellowarrow). Spleniumof the corpus callosum is visible (bluearrow).
(D) Post mortem image of P02’s liver (L), spleen (S), and duodenum (D). White arrow shows the orthotopic location of the pancreas,
which is absent. Dashed arrow indicated site in which the absent gallbladder would be expected to be.and the diagnosis could not therefore be confirmed. All
three individuals had very low birth weight (Z-score
< 2), likely due to insulin deficiency in the last trimester
of pregnancy, when insulin is the main fetal growth factor.
Consistent with insulin deficiency in utero, the three case
subjects all developed diabetes very early (2/3 diagnosed
at 1 day and 1 at 13 weeks). P01 and P02 also had gall-
bladder agenesis, a clinical feature frequently associated
with pancreatic agenesis.
The DDD study5 has identified de novo CNOT1 vari-
ants in three individuals with developmental delay
(two missense—p.Leu2323Phe and p.Arg623Trp—and a
nonsense—p.Gln33*—variant) but none of them had hol-
oprosencephaly or diabetes. Since our three case subjects
were all heterozygous for the same novel missense
CNOT1 variant and none of the DDD participants with
heterozygous de novo CNOT1 variants had pancreatic or
neurological structural malformations, we hypothesized
that a mutation-specific mechanism rather than loss of
function was responsible for the phenotype seen in our
case subjects. We therefore generated a mouse line
harboring the Cnot1p.(Arg535Cys) mutation using CRISPR
(Supplemental Subjects and Methods).
Heterozygous mice were born at a lower than expected
frequency (Table S5), but without an obvious phenotype,
while homozygosity for the mutation was embryonically
lethal. At E14.5, embryos were still alive and present at986 The American Journal of Human Genetics 104, 985–989, May 2,expected Mendelian ratios and were therefore collected
to assess their phenotype (Supplemental Subjects and
Methods). Upon dissection, several gross morphological
abnormalities were apparent in homozygotes, notably
exencephaly, eye defects (mostly coloboma), and edema
(Figures 2A, 2B, and S2; Table S6).
High-resolution episcopic microscopy (HREM) high-
lighted a significant reduction in the size of the pancreas
in homozygous embryos in addition to several other ab-
normalities (Figures 2C–2G, Supplemental Subjects and
Methods, DMDD website). The reduction in pancreatic
size was found to be predominantly due to a smaller dorsal
pancreas (Figures 2H and S3). These results provide
compelling evidence for the role of Cnot1p.(Arg535Cys) in
pancreatic development.
Expression analysis of pancreatic developmental factors
on RNA extracted from pancreatic tissue in E14.5 wild-
type, Cnot1p.(Arg535Cys)/p.(Arg535Cys), and Cnot1p.(Arg535Cys)
embryos showed a significant increase of Shh expression in
homozygous embryos, with decreased expression in Pdx1,
Ins,Hnf1b, and Ptf1a (Figure 3A).Nodifference in expression
was detected for Gata6 (Figure 3A) and Rxra (Figure S4).
The pancreatic and neurological phenotypes observed in
Cnot1p.(Arg535Cys)/p.(Arg535Cys) E14.5 mouse embryos are
consistent with the pancreatic agenesis and holoprosence-
phaly observed in the three case subjects, confirming that
the de novo CNOT1 mutation is indeed the cause of their2019
Figure 2. Neurological and Pancreatic Abnormalities in Mouse Embryos Homozygous for the Cnot1 p.Arg535Cys Mutation
(A) Table listing the gross external phenotypes observed in E14.5 embryos. Numbers do not add to total as many embryos displayedmul-
tiple phenotypes. Significance by Fisher’s exact test, assuming an additive model. Exencephaly, p ¼ 3.2 3 109; spina bifida, p ¼ 0.027;
eye defect, p ¼ 5.5 3 108; edema, p ¼ 2.6 3 107; midline defect, ns.
(B) Images showing representative E14.5 embryos: top shows wild-type embryo, bottom shows embryo homozygous for the CNOT1
p.Arg535Cys mutation with exencephaly and coloboma.
(C and E) Coronally sectioned, semi-transparent 3D volume models of stage-matched E14.5 embryos with superimposed models of the
pancreas of homozygous (C) and wild-type (E) embryos.
(D) Overlay of extracted surface models of the pancreas of homozygous (blue, magenta) and wild-type embryos (orange, green).
(F and G) Coronally sectioned solid 3D volume renderedmodel of the abdomen of the embryos shown in (C) and (E) with superimposed
pancreas. dp, dorsal pancreas; vp, ventral pancreas; li, liver lobes; s, stomach; sp, spleen; k, kidney; g, gonad; bd, bile duct.
Scale bars: 1,000 mm in (C), (E)–(G); 500 mm in (D).
(H) Graph showing the volume of the dorsal pancreas of E14.5 embryos in mm3. Blue squares show wild types, green circles are hetero-
zygotes, and red triangles are homozygotes. Data analyzed using ANOVAwith TukeyHSD posthoc test, effect of genotype p¼ 8.853 108;
post hoc WT-Hom, p < 1010; Het-Hom, p ¼ 1.36 3 104, WT-Het, ns.disease. Mice required a homozygous mutation in Cnot1
to display a pancreatic and brain phenotype while a
heterozygous CNOT1 mutation resulted in the phenotype
in three individuals in our cohort. This has been described
with other pancreatic developmental genes (e.g., HNF1B)
and supports the hypothesis that the early stages of
pancreatic development are not identical in mice and
humans.6
The CNOT1 protein has not previously been suggested
to have a role in pancreatic development; it is known to
act both as scaffold of the CCR4-NOT complex and as an
independent factor. As such, it mediates transcriptional
repression7 and is expressed extremely early during embry-
onic development (E3.5 in the inner cell mass in mice8).
In vitro studies have proposed that CNOT1 plays a critical
role in maintaining human andmice embryonic stem cells
in a pluripotent state by inhibiting primitive endoderm
factors.8 CNOT1 expression peaks in undifferentiatedThe Amehuman induced pluripotent stem (iPS) cells compared to
subsequent stages of in vitro differentiation toward pancre-
atic endocrine cells,9 supporting its fundamental role in
stem cells.
The increased expression of Shh in pancreatic tissue
extracted fromCnot1p.(Arg535Cys)/p.(Arg535Cys) embryos would
be consistent with a model in which the CNOT1
p.Arg535Cys mutation results in embryonic stem cells
being maintained in an undifferentiated state through
SHH-mediated inhibition of differentiation. SHH is a key
developmental factor that is known to be crucial for pancre-
atic and brain development. Heterozygous loss-of-function
mutations in SHH cause holoprosencephaly (MIM: 142945)
and studies in bothmouse andhuman embryoshave shown
that SHH expression needs to be repressed in the dorsal fore-
gut endoderm for successful differentiation toward dorsal
pancreas.6,10A recent studyhas suggested that the transcrip-
tion factors Gata4 and Gata6 (mutations in which are arican Journal of Human Genetics 104, 985–989, May 2, 2019 987
Figure 3. Expression Data and Possible
Mechanism Involving CNOT1 in Pancre-
atic Development
(A) Graphs showing relative expression of
genes in the pancreas of E14.5 embryos.
Bars showmean5 SE. Data analyzed using
ANOVA with TukeyHSD posthoc test.
Results of posthoc tests shown on graphs,
*p < 0.05, **p < 0.01, ***p < 0.001. Shh,
effect of genotype p ¼ 0.0107; Pdx1, effect
of genotype p ¼ 0.0189; Ins, effect of geno-
type p¼ 7.033 106;Hnf1b, effect of geno-
type p ¼ 0.0294; Ptf1a, effect of genotype
p ¼ 0.00781; Gata6, effect of genotype
p ¼ ns. n ¼ 4–12 animals per genotype.
(B) Schematic representation of the pro-
posed role for CNOT1 in pancreatic
development.cause of pancreatic agenesis) regulate pancreatic endoderm
identity by directly inhibiting Shh in mice.11 It is therefore
possible that the p.Arg535Cys variant results in CNOT1
maintaining its inhibition activity on the GATA and other
early differentiation factors and, as a consequence, SHH
expression is not repressed (Figure 3B). Increased expression
of Shh and decreased expression of Pdx1, Ins, Hnf1b, and
Ptf1a detected in RNA extracted from pancreatic tissue in
the E14.5 Cnot1p.(Arg535Cys)/p.(Arg535Cys) embryos would sup-
port this hypothesis. However, Gata4 expression could not
be assessed as the assay specificity was too low and Gata6
expression was not found to be reduced. It is possible that
Gata6 activity is actually inhibited earlier during develop-
ment and then re-activated by a different pathway (Gata6
is needed for development of most endodermal-derived or-
gans and heart) or could be inhibited by a different mecha-
nism thatdoesnot result in reduced expression. TheCNOT1
p.Arg535Cys mutation also affects neurological develop-
ment in both our case subjects and mouse embryos. It is
possible that this mutation results in ectopic SHH expres-988 The American Journal of Human Genetics 104, 985–989, May 2, 2019sion during brain development. This
would be consistent with previous re-
ports of Shhectopic expression impair-
ing midline development.12 Another
possibility is that the effect of the
CNOT1 mutation on SHH signaling
differs between the brain and the
pancreas, resulting ina reducedexpres-
sion in the developing brain and
increased expression during pancre-
atic development. Further experi-
ments, ideally on younger embryos
and human iPS cells, are needed in or-
der to elucidate the mechanism by
which the CNOT1 p.Arg535Cys muta-
tion results in impaired pancreatic and
neurological development.
Our study identifies a spontaneous
CNOT1 p.Arg535Cys mutation as the
genetic cause of a rare syndrome ofpancreatic agenesis and holoprosencephaly, highlighting
a previously unsuspected role of CNOT1 as a key factor
in both pancreatic and neurological development. This is
the 7th gene causative of pancreatic agenesis described so
far and the first pancreatic agenesis gene that is thought
to be important for maintaining stem cells’ pluripotency.
These findings suggest a newmechanism by which impair-
ment of the very early stages of development result in
pancreatic agenesis and abnormal brain development.
Supplemental Data
Supplemental Data can be found online at https://doi.org/10.
1016/j.ajhg.2019.03.018.
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